Basic mechanisms of hepatocellular injury. Role of inplammatory lipid mediators;Mecanismos básicos de lesión hepatocelular. Papel de los mediadores lipídicos de inflamación

Gastroenterologia y Hepatologia

Volumn 31, Issue 10, 2008, Pages 682-692

  Clària, Juan ^a,b   Horrillo, Raquel ^a   Martínez Clemente, Marcos ^a   Morán Salvador, Eva ^a   Titos, Esther ^a   González Périz, Ana ^a   Ferré, Natàlia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; ANTIOXIDANT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CJ 13610; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPENTANE; CYTOKINE; GROWTH FACTOR; INFLIXIMAB; ISOPROSTANE; LIPID; LIPOXYGENASE; METHIONINE; OMEGA 3 FATTY ACID; OXYGEN RADICAL; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC;

ALCOHOL LIVER DISEASE; CELL ACTIVATION; CELL DAMAGE; CELL INFILTRATION; CHOLESTASIS; CHRONIC LIVER DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; FATTY LIVER; HUMAN; INFLAMMATION; INFLAMMATORY CELL; KUPFFER CELL; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER NECROSIS; LIVER PROTECTION; MEDIATOR RELEASE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARENCHYMA; PATHOGENESIS; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS;

EID: 60149111891     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/s0210-5705(08)75816-3     Document Type: Review

References (117)

1. Rodés J, Benhamou J-P, Blei A, Reichen J, Rizzetto M, editors. The textbook of hepatology: from basic science to clinical practice. 3rd ed. Malden: Blackwell Publishing; 2007.
2. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology. 2006;43:31-44.
3. Mandrekar P. Signaling mechanisms in alcoholic liver injury: role of transcription factors, kinases and heat shock proteins. World J Gastroenterol. 2007;13:4979-85.
4. Guicciardi ME, Gores GJ. Cholestatic hepatocellular injury: what do we know and how should we proceed. J Hepatol. 2005;42:297-300.
5. Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol. 2007;4:622-34.
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.
7. Clària J, Titos E. Kupffer cell. Gastroenterol Hepatol. 2004;27:264-73.
8. Munthe-Kaas AC. Phagocytosis in rat Kupffer cells in vitro. Exp Cell Res. 1976;99:319-27.
9. Fox ES, Broitman SA, Thomas P. Bacterial endotoxins and the liver. Lab Invest. 1990;63:733-41.
10. Van Bossuyt H, Wisse E. Cultured Kupffer cells, isolated from human and rat liver biopsies, ingest endotoxin. J Hepatol. 1988;7:45-56.
11. Rogoff TM, Lipsky PE. Role of the Kupffer cells in local and systemic immune responses. Gastroenterology. 1981;80:854-60.
12. Ferré N, Clària J. New insights into the regulation of liver inflammation and oxidative stress. Mini Rev Med Chem. 2006;6:1321-30.
13. Jaeschke H, Bautista AP, Spolarics Z, Spitzer JJ. Superoxide generation by neutrophils and Kupffer cells during in vivo reperfusion after hepatic ischemia in rats. J Leukoc Biol. 1992;52:377-82.
14. Johnson SJ, Hines JE, Burt AD. Macrophage and perisinusoidal cell kinetics in acute liver injury. J Pathol. 1992;166:351-358-72.
15. Winwood PJ, Arthur MJ. Kupffer cells: their activation and role in animal models of liver injury and human liver disease. Semin Liver Dis. 1993;13:50-9.
16. Edwards MJ, Keller BJ, Kauffman FC, Thurman RG. The involvement of Kupffer cells in carbon tetrachloride toxicity. Toxicol Appl Pharmacol. 1993;119:275-9.
17. Arthur MJ, Bentley IS, Tanner AR, Saunders PK, Millward-Sadler GH, Wright R. Oxygen-derived free radicals promote hepatic injury in the rat. Gastroenterology. 1985;89:1114-22.
18. Knecht KT, Adachi Y, Bradford BU, Iimuro Y, Kadiiska M, Xuang QH, et al. Free radical adducts in the bile of rats treated chronically with intragastric alcohol: inhibition by destruction of Kupffer cells. Mol Pharmacol. 1995;47:1028-34.
19. Enomoto N, Ikejima K, Yamashina S, Enomoto A, Nishiura T, Nishimura T, et al. Kupffer cell-derived prostaglandin E(2) is involved in alcohol-induced fat accumulation in rat liver. Am J Physiol Gastrointest Liver Physiol. 2000;279:100G-6G.
20. Maher JJ. Rat hepatocytes and Kupffer cells interact to produce interleukin-8 (CINC) in the setting of ethanol. Am J Physiol. 1995;269:518G-23G.
21. Thornton AJ, Ham J, Kunkel SL. Kupffer cell-derived cytokines induce the synthesis of a leukocyte chemotactic peptide, interleukin-8, in human hepatoma and primary hepatocyte cultures. Hepatology. 1991;14:1112-22.
22. Shiratori Y, Takada H, Hikiba Y, Nakata R, Okano K, Komatsu Y, et al. Production of chemotactic factor, interleukin-8, from hepatocytes exposed to ethanol. Hepatology. 1993;18:1477-82.
23. Vessey DA. Metabolism of xenobiotics by the human liver. En: Zakim D, Boyer TD, editors. Hepatology. A text book of liver disease. 4th ed. Philadelphia: WB Saunders; 2002. p. 257-352.
24. Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis. 1996;16:343-8.
25. Mathew J, Hines JE, James OF, Burt AD. Non-parenchymal cell responses in paracetamol (acetaminophen)-induced liver injury. J Hepatol. 1994;20:537-41.
26. Caldwell-Kenkel JC, Currin RT, Tanaka Y, Thurman RG, Lemasters JJ. Kupffer cell activation and endothelial cell damage after storage of rat livers: effects of reperfusion. Hepatology. 1991;13:83-95.
27. Jaeschke H. Pathophysiology of hepatic ischemia-reperfusion injury: the role of complement activation. Gastroenterology. 1994;107:583-6.
28. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118:503.
29. Czaja MJ. TNF toxicity-death from caspase or cathepsin, that is the question. Hepatology. 2001;34:844-6.
30. Heyninck, K, Wullaert A, Beyaert R. Nuclear factor-kappa B plays a central role in tumour necrosis factor-mediated liver disease. Biochem Pharmacol. 2003;66:1409-15.
31. Ladero JM, Fernández-Arquero M, Tudela JI, Agudez JA, Díaz-Rubio M, Benítez J, et al. Single nucleotide polymorphisms and microsatellite alleles of tumor necrosis factor alpha and interleukin-10 genes and the risk of advanced chronic alcoholic liver disease. Liver. 2002;22:245-51.
32. Tsuchiya N, Tokushige K, Yamaguchi N, Hasegawa K, Hashimoto E, Yamauchi K, et al. Influence of TNF gene polymorphism in patients with acute and fulminant hepatitis. J Gastroenterol. 2004;39:859-66.
33. Leist M, Ganter, F, Bohlinger I, Tiegs G, Germann PG, Wendel A. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am J Pathol. 1995;146:1220-34.
34. Leist M, Gantner F, Jilg S, Wendel A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol. 1995;154;1307-16.
35. Simeonova P, Gallucci RM, Hulderman T, Wilson R, Kommineni C, Rao M, et al. The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. Tox Appl Pharm. 2001;177:112-20.
36. Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin North Am. 2004;33:387-406.
37. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-9.
38. Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev. 2007;6:529-36.
39. Spahr L, Rubbia-Brandt L, Frossard J, Giostra E, Rougemont A, Pugin J, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol. 2002;37:448-55.
40. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003;38:419-25.
41. Naveau S, Collet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39:1390-7.
42. Ueno Y, Tanaka S, Shimamoto M, Mikanaya Y, Himaya T, Ito M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Digest Dis Sci. 2005;50:163-6.
43. Magro F, Pereira P, Carneiro F, Veloso FT. Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis? Inflamm Bowel Dis. 2005;11:88-90.
44. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-18.
45. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA. 1995;92:2572-6.
46. Shek FW, Benyon RC. How can transforming growth factor beta be targeted usefully to combat liver fibrosis. Eur J Gastroenterol Hepatol. 2004;16:123-6.
47. Dryden GW Jr, Deaciuc I, Arteel G, McClain CJ. Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep. 2005;7:308-16.
48. Rojkind M, Domínguez-Rosales JA, Nieto N, Greenwel P. Role of hydrogen peroxide and oxidative stress in healing responses. Cell Mol Life Sci. 2002;59:1872-91.
49. Balsinde J, Winstead MV, Dennis EA. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett. 2002;531:2-6.
50. Dudzinski DM, Serhan CN. Pharmacology of eicosanoids. En: Golan AH, Tashjian EJ, Amstrong C, et al, editors. Principles of pharmacology. The pathophysiologic basis of drug therapy. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 627-46.
51. Romano M, Clària J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. 2003;17:1986-95.
52. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987;237:1171-6.
53. Clària J. Cyclooxygenase-2 biology. Curr Pharm Des. 2003;9:2177-90.
54. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol. 2001;41:661-90.
55. Clària J, López-Parra M. New perspectives in the modulation of the eicosanoid cascade in inflammation. Letters in Drug Design and Discovery. 2005;2:391-402.
56. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature. 1971;231:232-5.
57. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323:645-55.
58. Decker K. Eicosanoids, signal molecules of liver cells. Semin Liver Dis. 1985;5:175-90.
59. Keppler D, Huber M, Baumert T. Leukotrienes as mediators in diseases of the liver. Semin Liver Dis. 1988;8:357-66.
60. Planagumà A, Titos E, López-Parra M, Gaya J, Pueyo G, Arroyo V, et al. Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. FASEB J. 2002;16:1937-9.
61. Titos E, Clària J, Bataller R, Bosch-Marcé M, Ginès P, Jiménez W, et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology. 2000;119:794-805.
62. Perez HD, Roll FJ, Bissell DM, Shak S, Goldstein IM. Production of chemotactic activity for polymorphonuclear leukocytes by cultured rat hepatocytes exposed to ethanol. J Clin Invest. 1984;74:1350-7.
63. Habib GM, Cuevas AA, Barrios R, Lieberman MW. Mouse leukotriene A4 hydrolase is expressed at high levels in intestinal crypt cells and splenic lymphocytes. Gene. 1999:234:249-55.
64. Núñez O, Fernández-Martínez A, Majano PL, Apolinario A, Gómez-Gonzalo M, Benedicto I, et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut. 2004;53:1665-72.
65. Mohammed NA, El Aleem SA, El Hafiz HA, McMahon RF. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J Clin Pathol. 2004;57:350-4.
66. Cheng J, Imanishi H, Iijima H, Shimomura S, Yamamoto T, Amuro Y, et al. Expression of cyclooxygenase 2 and cytosolic phospholipase A(2) in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol Res. 2002;23:185-95.
67. Cheng AS, Chan HL, Leung WK, To KF, Go MY, Chan JY, et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol. 2004;17:1169-79.
68. Planagumà A, Clària J, Miquel R, López-Parra M, Titos E, Masferrer JL, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving nonparenchymal cell apoptosis and PPARgamma activation. FASEB J. 2005;19:1120-2.
69. Nanji AA, Zakim D, Rahemtulla A, Daly T, Miao L, Zhao S, et al. Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat. Hepatology. 1997;26:1538-45.
70. Nanji AA, Miao L, Thomas P, Rahemtulla A, Khwaja S, Zhao S, et al. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat. Gastroenterology. 1997;112:943-51.
71. Yu J, Ip E, Dela Pena A, Hou JY, Sesha J, Pera N, et al. COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology. 2006;43:826-36.
72. Yamamoto H, Kondo M, Shoji N, Nagano H, Wakasa KI, Sugita Y, et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology. 2003;125:556-71.
73. De la Pena A, Leclercq IA, Williams J, Farrell GC. NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. J Hepatol. 2007;46:304-13.
74. Yu J, Hui AY, Chu ES, Cheng AS, Go MY, Chan HL, et al. Expression of a COX-2 transgene in murine liver causes hepatitis. Gut. 2006;56:991-9.
75. Waris G, Siddiqui A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol. 2005;79:9725-34.
76. Hui AY, Cheng AS, Chan HL, Go MY, Chan FK, Sakata R, et al. Effect of prostaglandin E2 and prostaglandin I2 on PDGF-induced proliferation of LI90, a human hepatic stellate cell line. Prostaglandins Leukot Essent Fatty Acids. 2004;71:329-33.
77. Kim KM, Yoon JH, Gwak GY, Kim W, Lee SH, Jang JJ, et al. Bile acid-mediated induction of cyclooxygenase-2 and Mcl-1 in hepatic stellate cells. Biochem Biophys Res Commun. 2006;342:1108-13.
78. Efsen E, Bonacchi A, Pastacaldi S, Valente AJ, Wenzel UO, Tosti-Guerra C, et al. Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. Hepatology. 2001;33:713-21.
79. Mallat A, Gallois C, Tao J, Habib A, Maclouf J, Mavier P, et al. Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors. J Biol Chem. 1998;273:27300-5.
80. Cheng J, Imanishi H, Liu W, Iwasaki A, Ueki N, Nakamura H, et al. Inhibition of the expression of alpha-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398. Biochem Biophys Res Commun. 2002;297:1128-34.
81. Bataller R, Gines P, Nicolas JM, Gorbig MN, García-Ramallo E, Gasull X, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149-56.
82. Davies RA, Knight B, Tian YW, Yeoh GC, Olynyk JK. Hepatic oval cell response to the choline-deficient, ethionine supplemented model of murine liver injury is attenuated by the administration of a cyclo-oxygenase 2 inhibitor. Carcinogenesis. 2006;27:1607-16.
83. Reding T, Bimmler D, Perren A, Sun LK, Fortunato F, Storni F, et al. A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. Gut. 2006;55:1165-73.
84. Horrillo R, Planagumà A, González-Périz A, Ferré N, Titos E, Miquel R, et al. Comparative protection against liver inflammation and fibrosis by a selective COX-2 inhibitor and a nonredox-type 5-LO inhibitor. J Pharmacol Exp Ther. 2007;323:778-86.
85. López-Parra M, Clària J, Titos E, Planagumà A, Párrizas M, Masferrer JL, et al. The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPAR gamma. Influence of albumin. J Hepatol. 2005;42:75-81.
86. Graupera M, Garcia-Pagan JC, Titos E, Clària J, Massaguer A, Bosch J, et al. 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology. 2002;122:387-93.
87. Muller D, Enderle GJ, Low O, Dietze E, Krell H. Bile ductular proliferation and altered leukotriene elimination in thioacetamide-induced fibrosis of rat liver. J Hepatol. 1996;25:547-53.
88. Uemura M, Buchholz U, Kojima H, Keppler A, Hafkemeyer P, Fukui H, et al. Cysteinyl leukotrienes in the urine of patients with liver diseases. Hepatology. 1994;20:804-12.
89. Clària J, Titos E, Jiménez W, Ros J, Ginés P, Arroyo V, et al. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology. 1998;115:147-56.
90. Baud L, Pérez, J, Denis M, Ardaillou R. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J Immunol. 1987;138:1190-5.
91. Baud L, Sraer J, Pérez J, Nivez MP, Ardaillou R. Leukotriene C4 binds to human glomerular epithelial cells and promotes their proliferation in vitro. J Clin Invest. 1985;76:374-7.
92. Phan SH, McGarry BM, Loeffler KM, Kunkel SL. Binding of leukotriene C4 to rat lung fibroblasts and stimulation of collagen synthesis in vitro. Biochemistry. 1988;27:2846-53.
93. Titos E, Clària J, Planagumà A, López-Parra M, Villamor N, Párrizas M, et al. Inhibition of 5-Lipoxygenase Induces Cell Growth Arrest and Apoptosis in Rat Kupffer Cells. Implications in liver fibrosis. FASEB J. 2003;17:1745-7.
94. Titos E, Clària J, Planagumà A, López-Parra M, González-Périz A, Gaya J, et al. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. J Leukoc Biol. 2005;78:871-8.
95. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996;23:749-54.
96. Federico A, Trappoliere M, Tuccillo C, De Sio I, Di Leva A, Del Vecchio Blanco C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut. 2006;55:901-2.
97. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev. 2001;21:185-210.
98. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-12.
99. Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 1999;20:1905-11.
100. Wilmer WA, Dixon C, Lu L, Hilbelink T, Rovin BH. A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPAR gamma. Biochem Biophys Res Commun. 2001;16;281:57-62.
101. Maddox JF, Domsalski AC, Roth RA, Ganey PE. 15-deoxy prostaglandin J2 enhances allyl alcohol-induced toxicity in rat hepatocytes. Toxicol Sci. 2004;77:290-298.
102. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther. 1991;49:153-79.
103. Sigal E, Laughton CW, Mulkins MA. Oxidation, lipoxygenase, and atherogenesis. Ann N Y Acad Sci. 1994;714:211-24.
104. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res. 1997;36:1-21.
105. Morrow JD, Chen Y, Brame CJ, Yang J, Sánchez SC, Xu J, et al. The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metab Rev. 1999;31:117-39.
106. Moore K, Roberts LJ 2nd. Measurement of lipid peroxidation. Free Radic Res. 1998;28:659-71.
107. Moore K. Isoprostanes and the liver. Chem Phys Lipids. 2004;128:125-33.
108. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ 2nd. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA. 1992;89:10721-5.
109. Brault S, Martínez-Bermúdez AK, Roberts J 2nd, Cui QL, Fragoso G, Hemdan S, et al. Cytotoxicity of the E(2)-isoprostane 15-E(2t)-IsoP on oligodendrocyte progenitors. Free Radic Biol Med. 2004;37:358-66.
110. Morrow JD, Awad JA, Kato T, Takahashi K, Badr KF, Roberts LJ 2nd, et al. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J Clin Invest. 1992;90:2502-7.
111. Meagher EA, Barry OP, Burke A, Lucey MR, Lawson JA, Rokach J, et al. Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest. 1999;104:805-13.
112. Nanji AA, Khwaja S, Tahan SR, Sadrzadeh SM. Plasma levels of a novel noncyclooxygenase-derived prostanoid (8-isoprostane) correlate with severity of liver injury in experimental alcoholic liver disease. J Pharmacol Exp Ther. 1994;269:1280-5.
113. Jain SK, Pemberton PW, Smith A, McMahon RF, Burrows PC, Aboutwerat A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol. 2002;36:805-11.
114. Aboutwerat A, Pemberton PW, Smith A, Burrows PC, McMahon RF, Jain SK, et al. Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim Biophys Acta. 2003;1637:142-50.
115. Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, Baer T, et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol. 2006;176:1848-59.
116. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman J, Petasis NA, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA. 2005;102:7671-6.
117. González-Périz A, Planagumà A, Gronert K, Miquel R, López-Parra M, Titos E, et al. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J. 2006;20:2537-9.